Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression.
Publication/Presentation Date
1-1-2014
Abstract
Intramuscular (IM) administration of adeno-associated viral (AAV) vectors has entered the early stages of clinical development with some success, including the first approved gene therapy product in the West called Glybera. In preparation for broader clinical development of IM AAV vector gene therapy, we conducted detailed pre-clinical studies in mice and macaques evaluating aspects of delivery that could affect performance. We found that following IM administration of AAV8 vectors in mice, a portion of the vector reached the liver and hepatic gene expression contributed significantly to total expression of secreted transgenes. The contribution from liver could be controlled by altering injection volume and by the use of traditional (promoter) and non-traditional (tissue-specific microRNA target sites) expression control elements. Hepatic distribution of vector following IM injection was also noted in rhesus macaques. These pre-clinical data on AAV delivery should inform safe and efficient development of future AAV products.
Volume
9
Issue
11
First Page
112268
Last Page
112268
ISSN
1932-6203
Published In/Presented At
Greig, J. A., Peng, H., Ohlstein, J., Medina-Jaszek, C. A., Ahonkhai, O., Mentzinger, A., Grant, R. L., Roy, S., Chen, S. J., Bell, P., Tretiakova, A. P., & Wilson, J. M. (2014). Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PloS one, 9(11), e112268. https://doi.org/10.1371/journal.pone.0112268
Disciplines
Medicine and Health Sciences
PubMedID
25393537
Department(s)
Department of Surgery
Document Type
Article